Home-Based Visual Evoked Potential EEG Shows Feasibility in Telemonitoring

Researchers have published a feasibility and usability study of home-based visual evoked potential (VEP) electroencephalogram recording, a modality traditionally confined to hospital neurophysiology laboratories. The work, reported in a Science Partner Journal, examines whether patients can obtain diagnostic-grade evoked potential data in their own homes as part of neurological telemonitoring research.

Visual evoked potentials are scalp EEG responses time-locked to visual stimulation, most often pattern-reversal checkerboards, and clinicians use them routinely to assess optic pathway integrity in conditions such as multiple sclerosis and optic neuritis. Until now, the standard of care has required patients to travel to a laboratory, where a technician applies the electrode montage and supervises acquisition.

The study addresses two questions that matter for any reading room considering remote neurophysiology: can unsupervised or lightly supervised home setups yield VEP waveforms of adequate quality, and can patients operate the equipment without specialist support. According to the publication, the investigators assessed both feasibility, meaning the technical success of home recordings, and usability, meaning the patient experience of performing them.

What does this change for clinical practice?

For neurophysiology services, the practical implication is a possible route to longitudinal monitoring without repeated clinic visits. Diseases that damage the visual pathway often require serial VEP testing, and home acquisition could increase testing frequency while reducing patient burden and travel costs.

The study remains research-stage. The publication describes telemonitoring research rather than an FDA-cleared home VEP device, and readers should distinguish this investigational work from currently cleared clinical systems. No home VEP platform should enter routine diagnostic use before validation against laboratory recordings in larger cohorts.

For EEG technologists and clinical neurophysiologists, the findings signal a likely shift in workflow: remote patient training, quality control of self-applied recordings, and centralized review of data acquired off-site. Reading rooms that already handle remote EEG review for epilepsy monitoring may find the model familiar.

The publication did not specify the exact cohort size, electrode system, or stimulation hardware used, and those details will determine how far the results generalize. Journals and reviewers will want device specifications, montage details, and test-retest reliability figures before home VEP enters broader discussion.

Future studies will need to establish diagnostic agreement between home-acquired and laboratory-acquired VEPs, define quality thresholds for interpretable home recordings, and test the approach in the specific patient populations, such as multiple sclerosis, that drive most clinical VEP demand.